Diabetes
News
Empagliflozin cut PA pressures in heart failure patients
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time....
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
News
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
News
Gut bacteria linked to cardiovascular, other health conditions
“Microbiota and their metabolites ... could serve as potential therapeutic targets for the maintenance of health and prevention and treatment of...
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
News
Does metformin reduce risk for death in COVID-19?
“It is still unclear whether metformin is truly a miracle drug or whether it is simply used more often among people who are healthier and who do...
News
Guidance covers glycemia in dexamethasone-treated COVID-19 patients
The latest document from the COVID-19 response group of the Association of British Clinical Diabetologists is a response to the recent RECOVERY...